Use our HBOC Research Search tool to find and participate in research focused on hereditaty cancers. Need assistance getting started?
Men and women 18 years or old with an advanced solid tumor can participate if:
People are excluded if they:
Gregory M Cote, MD, PhD by phone: 617-724-4000 or by email
This clinical trial is studying how well M6620 works in treating patients with advanced solid tumors. M6620 is a drug designed to block the ATR enzyme. ATR repairs damaged DNA. In cancer, ATR may protect the cancer cells by helping them repair damage. Blocking ATR may keep cancers from repairing their damaged DNA; slowing the growth of, or killing cancer cells. The study is open to people with advanced solid tumors and a BRCA1, BRCA2 or ATM mutation. The study will be recruiting people with different types of cancer, including people with advanced solid tumors and a BRCA1, BRCA2 or ATM mutation.
The following are participating institutions: